CLCF1 inhibits energy expenditure via suppressing brown fat thermogenesis
成果类型:
Article
署名作者:
Yuan, Youwen; Li, Kangli; Ye, Xueru; Wen, Shiyi; Zhang, Yanan; Teng, Fei; Zhou, Xuan; Deng, Yajuan; Yang, Xiaoyu; Wang, Weiwei; Lin, Jiayang; Luo, Shenjian; Zhang, Peizhen; Shi, Guojun; Zhang, Huijie
署名单位:
Southern Medical University - China; Southern Medical University - China; Southern Medical University - China; Army Medical University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University
刊物名称:
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
ISSN/ISSBN:
0027-11667
DOI:
10.1073/pnas.2310711121
发表日期:
2024-01-16
关键词:
unfolded protein response
adipose-tissue
cytokine
pathways
insulin
weight
leptin
er
摘要:
Brown adipose tissue (BAT) is the main site of nonshivering thermogenesis which plays an important role in thermogenesis and energy metabolism. However, the regulatory factors that inhibit BAT activity remain largely unknown. Here, cardiotrophin-like cytokine factor 1 (CLCF1) is identified as a negative regulator of thermogenesis in BAT. Adenovirus-mediated overexpression of CLCF1 in BAT greatly impairs the thermogenic capacity of BAT and reduces the metabolic rate. Consistently, BAT-specific ablation of CLCF1 enhances the BAT function and energy expenditure under both thermoneutral and cold conditions. Mechanistically, adenylate cyclase 3 (ADCY3) is identified as a downstream target of CLCF1 to mediate its role in regulating thermogenesis. Furthermore, CLCF1 is identified to negatively regulate the PERK-ATF4 signaling axis to modulate the transcriptional activity of ADCY3, which activates the PKA substrate phosphorylation. Moreover, CLCF1 deletion in BAT protects the mice against diet-induced obesity by promoting BAT activation and further attenuating impaired glucose and lipid metabolism. Therefore, our results reveal the essential role of CLCF1 in regulating BAT thermogenesis and suggest that inhibiting CLCF1 signaling might be a potential therapeutic strategy for improving obesity-related metabolic disorders.